Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 3Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Multiple Myeloma 49Leukemia, Lymphocytic, Chronic, B-Cell 19Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma 12Recurrence 10Lymphoma, Mantle-Cell 9Lymphoma, Follicular 7Leukemia, Myeloid, Acute 7Waldenstrom Macroglobulinemia 6Neoplasms, Plasma Cell 6Myelodysplastic Syndromes 6Lymphoma, B-Cell, Marginal Zone 6Leukemia 6Lymphoma, T-Cell, Peripheral 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Burkitt Lymphoma 4Sezary Syndrome 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3

Interventions

Carboplatin 44Paclitaxel 43liposomal doxorubicin 23Topotecan 19Gemcitabine 18pembrolizumab 17Cyclophosphamide 17Bevacizumab 16Cisplatin 12niraparib 9olaparib 8fludarabine 7Taxes 7Docetaxel 7aldesleukin 6Nivolumab 6Doxorubicin 61-dodecylpyridoxal 6oregovomab 5fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5rucaparib 4durvalumab 4avelumab 4Surgical Procedures, Operative 4Melphalan 4Ipilimumab 4Interleukin-2 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Ovarian Neoplasms × Lenalidomide × Clear all
NCT00903630 2017-12-28

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
15 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01202890 2014-01-08

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

New Mexico Cancer Research Alliance

Phase 1 Terminated
1 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00179725 2006-04-12

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Celgene

Phase 1/2 Terminated
60 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡